We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » COVID-19

COVID-19
COVID-19 RSS Feed RSS

First Real-World Data Suggest Omicron Illness May Be Less Severe

December 16, 2021
Adults infected with the Omicron variant are 29 percent less likely to enter the hospital than people infected with other COVID-19 strains, according to the first large-scale real-world clinical data. Read More

Pfizer’s Oral ‘At Home’ COVID-19 Treatment Candidate is 89 Percent Effective, Could Soon Grab Top Spot from Molnupiravir

December 15, 2021
Final data from the phase 2/3 study of Pfizer’s novel oral “at home” COVID-19 treatment, Paxlovid, was so strong, the candidate could be well-positioned to knock molnupiravir — which is authorized in the UK although not yet in the U.S. — off its perch. Read More

Oxford Study Says Two-Dose Vaccines Induce Lower Antibodies Against Omicron

December 14, 2021
The findings are in line with newly published data from the UK Health Security Agency, which showed reduced vaccine effectiveness against Omicron vs. the Delta variant. Read More

Two New Studies — And Pfizer — Confirm mRNA Vaccines Are Less Effective on Omicron

December 9, 2021
The Pfizer/BioNTech and Moderna COVID-19 vaccines are 25-40 times less effective against the new Omicron variant than the original strain and Delta variants, two new laboratory studies have found. Read More

Medicago Gets Positive Results on Plant-Based COVID-19 Vaccine Using GSK Booster

December 8, 2021
The world’s first plant-based COVID-19 vaccine just returned positive results in a late-stage study. Read More

Thermo Fisher Scientific to Manufacture Merck’s COVID-19 Pill

December 8, 2021
In the U.S., an FDA advisory committee narrowly backed authorizing molnupiravir last week, but the agency has yet to approve the COVID-19 pill for emergency use. Read More

WHO Says ‘No’ to Convalescent Plasma for Nonsevere COVID-19

December 8, 2021
The WHO said the evidence was less certain for severe and critically ill COVID-19 patients and suggested trials continue for this subgroup to gather more data. Read More

EMA Endorses Mix-and-Match of COVID-19 Vaccines

December 8, 2021
More data will be needed to support the use of mixing and matching of COVID-19 shots for immunosuppressed individuals, the agencies said. Read More

Gilead Sciences Recalls Remdesivir Lots Over Glass Particulates

December 7, 2021
Gilead Sciences has recalled two lots of its blockbuster COVID-19 antiviral Veklury (remdesivir) for possible contamination with glass particulates. Read More

FDA Updates EUA for Eli Lilly’s COVID-19 Antibody Cocktail to Include Young Children

December 6, 2021
The FDA has revised the Emergency Use Authorization (EUA) covering Eli Lilly’s COVID-19 antibody cocktail (bamlanivimab/etesevimab), enabling its use in children as young as babies with mild to moderate COVID-19 at high risk of progressing to severe disease. Read More

Many Vaccines Offer Protection as Boosters but Pfizer’s, Moderna’s May Work Best

December 6, 2021
Several different COVID-19 booster shot combinations appear to improve protection against infection but the messenger RNA (mRNA)-based jabs from Pfizer and Moderna might be the most effective. Read More

Court Rejects Moderna’s Challenge to Arbutus Biopharma Patents

December 3, 2021
A federal appeals court has struck down Moderna’s coronavirus vaccine-related challenge to patents held by Arbutus Biopharma. Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 167 168 Next

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing